ArticleClinical case reports2025
Case of Relapsed, Metastatic Cutaneous Squamous Cell Carcinoma With HER2 Mutation Treated With Trastuzumab.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case of Relapsed, Metastatic Cutaneous Squamous Cell Carcinoma With HER2 Mutation Treated With Trastuzumab.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous squamous cell carcinoma (SCC) is a common skin cancer with a favorable prognosis when diagnosed at an early stage and fully resected. While the risk of recurrence and metastasis is relatively low for most patients, management of unresectable or metastatic SCC can be challenging due to poor responses to chemotherapy and therapy-related toxicities. The HER family of receptor tyrosine kinases has been associated with cutaneous malignancies including SCC. However, the pathogenic influence and targetability of HER2 in cutaneous SCC are not well defined. Here, we describe a case of a patient initially presenting with metastatic SCC who underwent primary tumor resection, radiation, and four systemic therapies due to disease progression before her disease was found to harbor an ERBB2 (HER2) mutation; she was subsequently started on HER2 targeted therapy with trastuzumab and achieved a significant sustained response to treatment. This case demonstrates the clinical challenges of treating advanced SCC and highlights HER2 as a potentially targetable driver mutation. Future research is needed to evaluate the association of the HER family and cutaneous SCC, as HER2 may represent an effective therapeutic avenue for patients harboring this mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.